Tin tức & Cập nhật
Xem bài viết Da liễu
Xem

Upadacitinib provides robust, long-term control of moderate-to-severe AD
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).

Chamomile improves skin recovery in breast cancer patients with radiodermatitis
A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.

SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma
The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.





